Research compendium

Survodutide

Survodutide is a peptide studied for agonism at GLP-1 and glucagon receptors. Its liver literature distinguishes whether a biopsy-documented lesion changes from how plasma exposure behaves in cirrhosis. These related questions require different designs.

This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.

What is established and what remains a hypothesis

Keep source limits and editorial status visible. A proposed mechanism should not be presented as a confirmed property in every context.

Is the source the original work, a review or a later interpretation?
Has the observation been reproduced under independent conditions?
Does the material defined in the paper match the entity named in this entry?

Find readings for this question

Mechanism described in the literature

Dual agonism identifies the molecule’s pharmacological targets. The selected clinical studies do not isolate each receptor’s contribution; assigning an observed change exclusively to GLP-1 or glucagon would exceed their comparisons.

Classification

Dual GLP-1 and glucagon receptor agonist peptide

Other names

Survodutide
BI 456906

What the histological response meant

In phase 2 adults with MASH and F1–F3 fibrosis, histological MASH improvement without worsening fibrosis was more frequent with survodutide than placebo. This criterion is neither complete MASH resolution nor disappearance of fibrosis. The study period alone also does not establish outcomes for hepatic decompensation.

What the cirrhosis study examined

An open-label, nonrandomized study compared plasma exposure in people with different cirrhosis severity and reference participants. Main exposure measures were similar in those cohorts. This is a pharmacokinetic interpretation, not evidence of equivalent liver outcomes across populations.

Reading the studies together

Biopsy, noninvasive markers and plasma concentrations answer different questions. Identify the primary endpoint before interpreting exploratory results. Tolerability also belongs in the account: gastrointestinal symptoms occurred more often than with placebo in the adult histological trial.

Questions and answers

Does MASH improvement mean cirrhosis reversal?

No. The cited histological trial enrolled F1–F3 fibrosis and used a specific improvement definition; it did not establish reversal of cirrhosis.

Does similar exposure demonstrate the same response?

No. It describes concentrations over time. Biological response needs its own endpoints and comparisons.